此 乃 要 件 請 即 處 理 閣 下 如 對 本 通 函 任 何 方 面 或 應 採 取 的 行 動 有 任 何 疑 問，應 諮 詢 閣 下 的 股 票 經 紀 或 其 他 持 牌 證 券 交 易 商、銀 行 經 理、律 師、專 業 會 計 師 或 其 他 專 業 顧 問。 閣下如已售出或轉讓名下所有本公司股份，應立即將本通函送交買主或承讓人， 或 經 手 買 賣 或 轉 讓 的 銀 行、股 票 經 紀 或 其 他 代 理，以 便 轉 交 買 主 或 承 讓 人。 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 通 函 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 表 明 不 會 就 因 本 通 函 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 MediNet Group Limited 醫匯集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：8161） 有 關 出 售 恒 泉 有 限 公 司 全 部 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （股份代號：8161） 延遲寄發有關主要交易的通函 茲 提 述 本 公 司 日 期 為 2025 年 1 月 9 日 有 關 訂 立 買 賣 協 議 及 出 售 事 項 的 公 告（「 該 公 告」）。除另有界定外，本公告所用詞彙與該公告所界定者具有相同涵義。 承董事會命 醫匯集團有限公司 主席兼執行董事 陳志偉先生 MediNet Group Limited 香港，2025年2月18日 醫 匯 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） 誠如該公告所披露，本公司已就出售事項根據GEM上市規則第19.44條取得本公司 控股股東Medinet International Limited（ 持有23,400,000股股份，相當於該公告日期 本公司全部 已發行股本約56.25 % ）的書面批准， 以代替於本公司股東 大會上通過 決 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 MediNet Group Limited （股份代號：8161） 主要交易及附屬公司層面的關連交易 有關出售恒泉有限公司全部已發行股本 出售事項 本公 司欣 然宣 佈， 於2025 年1 月 9 日（ 交 易時段 後 ）， 賣方（ 本 公司 的全 資附 屬公 司 ）與 買 方 訂 立 買 賣 協 議 ， 據 此 ， 賣 方 有 條 件 同 意 出 售 ， 而 買 方 有 條 件 同 意 收 購銷售股份（ 相當於目標公司全部已發行股本 ），代價為14,400,000港元，並受買 賣協議的條款及條件所限。 醫 匯 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） 於完成後，目標公司將不再為本公司間接全資附屬公司，且目標公司的財務業 績將不再綜合計入本公司賬目內。 GEM上市規則的影響 由 於 出 售 事 項 的 最 高 適 用 百 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 MediNet Group Limited 醫 匯 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：8161） 公司秘書及授權代表變動 公司秘書及授權代表辭任 醫匯集團有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈，梁文輝先生（「梁 先生」）由於希望投放更多時間於其事業發展及個人事務，故此已辭任本公司公司 秘書（「公司秘書」），並不再擔任香港聯合交易所有限公司（「聯交所」）GEM證券上 市 規 則（「 GEM 上 市 規 則 」）第 5.24 條 所 規 定 本 公 司 的 授 權 代 表（「 授 權 代 表 」）， 自 2025年1月2日起生效。 謝先生，35歲，於2011年在澳洲昆士蘭大學畢業，獲得會計學學士學位。謝先生 為香港會計師公會及澳洲會計師公會的註冊會計師，亦為英國特許管理會計師公 會的特許 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 MediNet Group Limited 醫 匯 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：8161） 有關訂立租賃協議的 須予披露交易 董 事 會 宣 布 ， 於 2024 年 12 月 30 日 ， 醫 匯 醫 務 及 嘉 偉 男 仕 健 康（ 均 為 本 公 司 間 接 附 屬 公 司 ）（ 作 為 共 同 租 戶 ）與 業 主 就 租 賃 該 物 業 訂 立 租 賃 協 議 ， 每 月 租 金 為 148,538.50港元（ 不包括冷氣費、服務費、政府差餉及所有其他支出 ），自2025年 1月1日起至2026年12月31日止為期兩(2)年（ 包括首尾兩日 ）。 上市規則的涵義 根據香港財務報告準則第16號「租賃」，訂立租賃協議將使本集團須於其資產負 債表內確認該物業的租賃為使用權資產，因此根據GEM上 ...

Financial Performance - The group's revenue for the six months ended September 30, 2024, was approximately HKD 57.9 million, a decrease from HKD 58.1 million in the same period last year, representing a decline of about 0.4%[26] - The net loss attributable to owners of the company for the period was approximately HKD 916,000, compared to a loss of HKD 2.3 million in the previous year, indicating an improvement of about 59.8%[13][34] - The total comprehensive loss for the period was HKD 984,000, down from HKD 2.3 million in the prior year, reflecting a reduction of approximately 57.5%[34] - The group experienced a pre-tax loss of HKD 737,000, an improvement from a loss of HKD 2.3 million in the previous year, representing a reduction of approximately 67.7%[34] - The company reported a loss of HKD 916 million for the six months ended September 30, 2024, compared to a loss of HKD 2,270 million for the same period in 2023, indicating a significant improvement[120] Revenue Breakdown - Revenue from medical solutions provided to contract clients increased by 9.5% to HKD 20.932 million, compared to HKD 19.119 million in the previous period[132] - Revenue from self-paying patients for medical services rose by 5.5% to approximately HKD 12.839 million, up from HKD 12.173 million[132] - Revenue from dental services provided to self-paying patients decreased by 12.8% to approximately HKD 21.798 million, down from HKD 24.992 million[132] Cost Management - Employee costs increased to HKD 18.7 million from HKD 17.6 million, marking a rise of about 6.3%[34] - Medical and dental supplies costs decreased to HKD 3.6 million from HKD 5.1 million, a reduction of approximately 29.3%[34] - The group's medical and dental professional service expenses slightly decreased by 1.0% to approximately HKD 25.0 million from HKD 25.3 million[153] - Employee costs increased by approximately 6.5% to HKD 18.7 million, compared to HKD 17.6 million in the previous period, mainly due to an increase in the number of employees and annual salary adjustments[154] - The group reported a significant reduction of approximately 29.4% in the cost of medical and dental supplies, decreasing to about HKD 3.6 million from HKD 5.1 million[155] Dividends and Shareholder Value - The group did not recommend the payment of an interim dividend for the period[26] - No interim dividend is recommended for the period[173] - The management team plans to further strengthen the dental business and expand the group's revenue sources while controlling expenses to create sustainable value for shareholders[150] Assets and Liabilities - Total assets as of September 30, 2024, were HKD 29,277 million, slightly up from HKD 29,249 million as of March 31, 2024[98] - The total liabilities increased to HKD 37,595 million as of September 30, 2024, compared to HKD 35,771 million as of March 31, 2024[101] - The company's cash and bank balances decreased to HKD 15,009 million from HKD 17,325 million over the same period[98] - The company's inventory increased to HKD 662 million from HKD 581 million, reflecting a rise in stock levels[98] - The group's current ratio as of September 30, 2024, was 0.9 times, unchanged from March 31, 2024[139] Future Outlook - The group is focused on improving operational efficiency and reducing costs in response to the challenging market conditions[26] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[102] - The company is focusing on enhancing its operational efficiency and reducing costs in response to the current financial performance[102] Miscellaneous - The group reported other income of HKD 219,000, down from HKD 309,000, reflecting a decrease of about 29.1%[34] - Depreciation of property, plant, and equipment was HKD 674,000, down from HKD 827,000, indicating a decrease of about 18.5%[34] - The company's basic and diluted loss per share improved to HKD 2.202 from HKD 5.457 year-over-year[95] - The total revenue for the period was not explicitly stated but is implied to be under review for future guidance[99] - The company had a fair value adjustment of HKD 1,253,000 recognized in equity related to an interest-free loan provided to a shareholder[199]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 MediNet Group Limited 醫 匯 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：8161） 自願公告 有關可能出售事項之 不具法律約束力之諒解備忘錄 董事會宣佈，於2024年12月19日（ 交易時段後 ），賣方（ 本公司之全資附屬公司 ） 與買方於2024年12月19日就可能出售事項訂立不具法律約束力之諒解備忘錄。 一般事項 可能出售事項（ 倘落實 ）可能根據GEM上市規則構成本公司一項於附屬公司層面 之須予公佈及關連交易。可能出售事項之進一步詳情須受諒解備忘錄訂約方將 訂立之正式協議所規限，而本公司將根據GEM上市規則於正式協議簽立後適時 另行刊發公告。 股東及╱或投資者務請注意，由於訂約方並未簽立具約束力之正式文件且仍在 磋商過程中，故可能出售事項未必會進行。股東及╱或投資者於買賣本公司證 券 ...

Financial Performance - For the six months ended September 30, 2024, the company's revenue was approximately HKD 57.9 million, a decrease of about HKD 208,000 compared to the same period in 2023[5]. - The net loss attributable to owners of the company for the period was approximately HKD 916,000, compared to a net loss of approximately HKD 2.3 million for the same period in 2023[5]. - Total comprehensive loss for the six months ended September 30, 2024, was HKD 984,000, compared to HKD 2.3 million for the same period in 2023[9]. - Basic and diluted loss per share for the period was HKD 2.202, compared to HKD 5.457 for the same period in 2023[9]. - Total revenue for the six months ended September 30, 2024, was HKD 61,830,000, a decrease from HKD 58,083,000 for the same period in 2023[39]. - The company reported a pre-tax loss of HKD 2,283,000 for the six months ended September 30, 2024, compared to a pre-tax loss of HKD 737,000 for the same period in 2023[45]. - Basic loss per share for the six months ended September 30, 2024, was HKD (916), compared to HKD (2,270) for the same period in 2023[50]. - The company experienced a loss from operations of HKD (1,127,000) for the six months ended September 30, 2024, compared to a profit of HKD 501,000 in the previous year[39]. Revenue Breakdown - The external revenue from dental services was HKD 26,791,000, while medical services generated HKD 31,292,000 for the six months ended September 30, 2024[39]. - Revenue from providing medical solutions to corporate clients increased by approximately 9.5% to HKD 20.9 million from HKD 19.1 million in the previous period[69]. - Revenue from self-paying patients for medical services increased by approximately 5.5% to HKD 12.8 million from HKD 12.2 million in the previous period[70]. - Revenue from providing dental solutions to corporate clients increased by approximately 28.2% to HKD 2.3 million from HKD 1.8 million in the previous period[70]. - Revenue from self-paying patients for dental services decreased by approximately 12.8% to HKD 21.8 million from HKD 25.0 million in the previous period[70]. - Revenue from medical plans for insurance companies was HKD 14,767,000, slightly down from HKD 15,152,000 in the previous year[42]. Assets and Liabilities - As of September 30, 2024, total assets amounted to HKD 15,390 million, an increase from HKD 12,777 million as of March 31, 2024, representing a growth of approximately 20.5%[10]. - Total current liabilities increased to HKD 37,595 million as of September 30, 2024, up from HKD 35,771 million as of March 31, 2024, reflecting a rise of 5.1%[10]. - The company’s non-current liabilities, specifically lease liabilities, increased to HKD 4,514 million as of September 30, 2024, from HKD 2,802 million as of March 31, 2024, marking a rise of 60.9%[12]. - The total equity attributable to owners of the company decreased to HKD 2,648 million as of September 30, 2024, down from HKD 3,632 million as of March 31, 2024, a decline of 27.1%[15]. - The company’s total liabilities increased to HKD 37,595 million as of September 30, 2024, compared to HKD 35,771 million as of March 31, 2024, reflecting a growth of 5.1%[10]. Cash Flow - The company reported a net cash inflow from operating activities of HKD 2,107 million for the six months ended September 30, 2024, compared to HKD 770 million for the same period in 2023, indicating a significant increase of 173.5%[19]. - The company’s cash and cash equivalents decreased to HKD 15,009 million as of September 30, 2024, down from HKD 17,325 million as of March 31, 2024, a decline of 13.4%[19]. - The net cash used in financing activities was HKD 4,374 million for the six months ended September 30, 2024, compared to a net cash inflow of HKD 4,848 million for the same period in 2023[19]. Operational Highlights - The company incurred total employee costs of HKD 18,727,000 for the six months ended September 30, 2024, an increase from HKD 17,586,000 in the previous year[45]. - Employee costs increased by approximately 6.5% to HKD 18.7 million from HKD 17.6 million in the previous period, mainly due to an increase in the number of employees and annual salary adjustments[74]. - The company spent approximately HKD 134,000 on the purchase of property, plant, and equipment during the period, significantly lower than HKD 1,329,000 for the six months ended September 30, 2023[51]. - Medical and dental professional service expenses slightly decreased by 1.0% to approximately HKD 25.0 million from HKD 25.3 million in the previous period[73]. - Cost of medical and dental supplies significantly reduced by approximately 29.4% from about HKD 5.1 million to approximately HKD 3.6 million[76]. - Other expenses decreased by approximately 13.1% from about HKD 7.2 million to approximately HKD 6.2 million, primarily due to cost control measures[79]. Corporate Governance - The board of directors does not recommend the payment of an interim dividend for the period[5]. - The Audit Committee was established on May 19, 2016, in accordance with GEM Listing Rules, consisting of three independent non-executive directors[112]. - The Audit Committee's main responsibilities include reviewing and supervising internal controls and risk management systems[112]. - The executive directors as of the announcement date are Mr. Chan Chi Wai and Ms. Jiang Jie, with independent non-executive directors including Mr. Leung Po Han, Mr. Wong Wai Leung, and Mr. Ng Wai Hung[114]. Shareholder Information - The issued share capital of the company as of September 30, 2024, was HKD 10,400,000, with 41,600,000 shares outstanding[83]. - As of September 30, 2024, Medinet International Limited holds 23,400,000 shares, representing 56.25% of the company's issued share capital[99]. - NSD Capital Limited, Convoy Asset Management Limited, Favour Sino Holdings Limited, and Convoy (BVI) Limited each hold 7,800,000 shares, accounting for 18.75% of the company's issued share capital[99]. - The company has not purchased, sold, or redeemed any of its listed securities during the reporting period[104].

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內 容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本 公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 MediNet Group Limited 醫匯集團有限公司 公司秘書 梁文輝 香港，2024年11月12日 於本公告日期，執行董事為陳志偉先生及姜洁女士，獨立非執行董事為梁寶漢先 生，黃偉樑先生及吳偉雄先生。 本公告遵照聯交所GEM證券上市規則的規定，提供關於本公司的資料；董事共同 及 個 別 對 本 公 告 負 全 責 。 董 事 經 作 出 一 切 合 理 查 詢 後 確 認 ， 據 彼 等 所 深 知 及 確 信，本公告所載資料在所有重大方面均屬準確及完整，並無誤導或欺詐成份，且 並無遺漏任何其他事宜導致本公告或當中任何聲明有誤導成份。 本公告將由其刊登日期起最少七日於聯交所網站www.hkexnews.hk（ 就公告而言， 於「最新公司公告」網頁 ）登載。本公告亦將於本公司網站www.Medi Net Group.com 登載。 醫 匯 集 團 有 限 公 司 （於開曼群島註冊 ...

Financial Performance - The group's revenue for the fiscal year ending March 31, 2024, was approximately HKD 116.2 million, an increase of about 5.3% from HKD 110.4 million in the previous fiscal year[14]. - The loss attributable to the owners of the company for the fiscal year 2023/24 was approximately HKD 8.1 million, a significant reduction from HKD 24.9 million in the fiscal year 2022/23[14]. - Revenue from medical solutions provided to contract clients increased by 45.7%, from approximately HKD 27.7 million to HKD 40.4 million[15]. - Revenue from self-paying patients for medical services rose by 43.6%, from approximately HKD 17.5 million to HKD 25.2 million[15]. - Revenue from dental solutions provided to contract clients decreased by 22.3%, from approximately HKD 7.1 million to HKD 5.5 million[15]. - Revenue from self-paying patients for dental services also saw a decline of 22.2%, from approximately HKD 58.0 million to HKD 45.2 million[15]. - Other income decreased from approximately HKD 3.5 million in FY2022/23 to approximately HKD 561,000 in FY2023/24, mainly due to the absence of additional income from the Hong Kong government's employment support scheme[19]. - Medical and dental professional service expenses increased from approximately HKD 42.9 million in FY2022/23 to approximately HKD 50.3 million in FY2023/24, an increase of about 17.2%, consistent with the revenue growth[21]. - Employee costs slightly decreased from approximately HKD 37.8 million in FY2022/23 to approximately HKD 37.2 million in FY2023/24, a decline of about 1.6% due to a decrease in average employee salary levels[22]. - The company incurred financing costs of HKD 660,000, up from HKD 560,000, reflecting increased borrowing[199]. - Other income decreased significantly to HKD 561,000 from HKD 3,539,000, a decline of 84.1%[199]. Corporate Governance - The company emphasizes the importance of good corporate governance for long-term success and sustainable development[65]. - The board is committed to maintaining high corporate governance standards to enhance accountability and transparency, protecting shareholder interests[66]. - The company has adhered to the corporate governance code throughout the fiscal year ending March 31, 2024, with one exception regarding the separation of roles between the chairman and CEO[68]. - The company aims to provide satisfactory and sustainable returns to shareholders while managing overall business risks appropriately[67]. - The company has established a corporate governance framework and developed a series of policies and procedures to enhance governance practices[66]. - The board believes that the current structure of having the same individual serve as chairman and CEO is beneficial for implementing business strategies[68]. - The company will regularly review and improve its corporate governance practices in line with the latest developments[69]. - The board currently consists of five directors, including two executive directors and three independent non-executive directors[71]. - The board has complied with GEM listing rules by appointing at least three independent non-executive directors, representing at least one-third of the board[73]. - All independent non-executive directors have confirmed their independence in writing prior to their appointment[73]. - The board held a total of four meetings during the year, with all directors actively participating[79]. - The chairman, Mr. Chan, attended all board meetings and the annual general meeting[79]. - The company has adopted a standard code for regulating directors' securities transactions, ensuring compliance with GEM listing rules[78]. - The nomination committee is responsible for reviewing the board composition and evaluating the independence of non-executive directors[74]. - The board has established a governance policy and is satisfied with its performance[72]. - The company has established a governance framework with three committees: Audit Committee, Nomination Committee, and Remuneration Committee, primarily composed of independent non-executive directors[90]. - The Audit Committee is responsible for reviewing financial controls, internal monitoring, and risk management systems, ensuring adequate disclosure in financial reporting[93]. - The company has a policy in place to ensure board member diversity, considering various factors such as gender, age, and professional experience[86]. - The company’s chairman and CEO roles are held by the same individual, which the board believes provides strong and consistent leadership[84]. Shareholder Communication - The company has established a shareholder communication policy to ensure shareholder opinions and concerns are properly addressed[127]. - The company encourages shareholders to participate in annual general meetings and allows for proxy voting if they cannot attend[131]. - The company maintains effective communication with investors to enhance transparency and understanding of its business and developments[133]. - The company has multiple channels for ongoing communication with shareholders, including company announcements and its website[128]. Financial Position - The total assets of the group as of March 31, 2024, were approximately HKD 42.0 million, compared to approximately HKD 42.9 million in 2023[31]. - The current ratio as of March 31, 2024, was approximately 0.8 times, compared to approximately 0.9 times in 2023[32]. - The company has a distributable reserve of approximately HKD 3.6 million as of March 31, 2024[152]. - The company has no significant contingent liabilities, legal disputes, or potential lawsuits as of March 31, 2024[146]. - The company’s asset-liability ratio as of March 31, 2024, is approximately 4.39, a significant increase from 0.84 in 2023[149]. - The company has no assets pledged as collateral as of March 31, 2024[158]. - The company has sufficient financial resources to continue operations for the foreseeable future, adopting a "going concern" basis in preparing its consolidated financial statements[147]. - The company has no significant or material disputes with stakeholders in the 2023/24 fiscal year[140]. - The independent auditor's report confirms that the consolidated financial statements fairly reflect the group's financial position as of March 31, 2024[179]. Management and Leadership - Mr. Chan has over 35 years of experience in the corporate medical and dental solutions industry, having founded the group in 1994[46]. - Ms. Jiang has accumulated over 10 years of experience in business development and customer relationship management since joining the group in 2009[48]. - The company is focused on strategic planning and compliance under the leadership of its executive directors[46]. - The company has appointed Mr. Wu as a non-executive director of Luchai Culture Limited (formerly known as Jingji Smart Culture Holdings) since September 2023[59]. - The company has no internal audit department but will continue to assess the need for one annually, considering the cost-effectiveness of hiring external professionals[112]. - The company is committed to anti-corruption and anti-bribery initiatives, actively organizing training and investigations to foster a culture of integrity[112]. Revenue Recognition and Audit - The independent auditor's report emphasizes the importance of revenue recognition as a key audit matter due to the volume of transactions recorded in the business system[183]. - The auditor's procedures included testing the effectiveness of controls over data transfer from operational systems to the accounting system, ensuring the accuracy of recorded transactions[185]. - The company engaged an independent external valuer to assist in the valuation of goodwill, ensuring objectivity in the assessment process[184]. Future Outlook - The company aims to maintain close relationships with existing clients while exploring new business opportunities[9]. - Future focus will remain on providing medical and dental services to corporate clients and the general public[10]. - The company plans to enhance internal controls and address identified deficiencies to improve financial reporting and compliance[196].